Home > Gastroenterology > Cumulative exposure to tacrolimus tied to post liver transplant cancer risk

Cumulative exposure to tacrolimus tied to post liver transplant cancer risk


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Journal
American Journal of Transplantation
Reuters Health - 21/03/2022 - Higher cumulative exposure to tacrolimus in the first year after liver transplant was linked to a higher risk for de novo malignancies and recurrent liver cancer in a case-control study from Spain.  Researchers at 16 transplant centers studied 2,945 patients who underwent liver transplantation between 2010 and 2015 and were treated with tacrolimus, including 491 (19.7%) who developed cancer during a median follow up of 65 months. Incidence rates were 3.5/100 person-years for all type of tumors and 2.6/100 persons-years for de novo cancers.  After controlling for liver cancer, risk factors for posttransplant malignancy included age ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on